Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

GSK plc GSK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved pharma major GSK’s Exdensur (depemokimab), the first twice-yearly biological medicine for use as an add-on treatment for ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

The MarketWatch News Department was not involved in the creation of this content. -- SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for ...

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...